MedTrace Logo

Vaccine Against Escherichia Coli Infection

NCT02289794 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2016-02-11

No results posted yet for this study

Summary

This Phase I multi-center placebo controlled study is conducted in healthy women with a history of recurrent urinary tract infections (UTI) aged between 18 and 70 years.

Conditions

  • E.Coli Infections

Interventions

BIOLOGICAL

E.coli bioconjugate vaccine

Single dose, intramuscular injection (0.5 mL)

BIOLOGICAL

Placebo

Single dose, intramuscular injection (0.5 mL)

Sponsors & Collaborators

  • GlycoVaxyn AG

    lead INDUSTRY

Principal Investigators

  • Veronica Gambillara, PhD · GlycoVaxyn AG

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-07-31
Completion
2015-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289794 on ClinicalTrials.gov